Glenmark Pharmaceuticals informs about media release

21 Mar 2026 Evaluate
Glenmark Pharmaceuticals has informed that the company research-led, global pharmaceutical company, today announced the launch of GLIPIQ® (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2170.50 1.75 (0.08%)
27-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.65
Dr. Reddys Lab 1281.95
Cipla 1242.65
Zydus Lifesciences 896.60
Lupin 2334.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×